Anakinra (recombinant form of human IL-1 receptor antagonist) is approved in the USA for the treatment of moderate to severe RA with Mtx.[17] A combination of anti-TNF and anti-IL-1 therapy could be potentially dangerous. The gene discussed is IL1B; the disease is rheumatoid arthritis.